Literature DB >> 24118351

An exploratory split-face study of a dual-wavelength laser system on erythromelanosis follicularis faciei in Chinese population.

B Wang1, Y Wu, X Zhu, X-G Xu, H-D Chen, Y-H Li.   

Abstract

BACKGROUND: Erythromelanosis follicularis faciei (EFF) is clinically characterized by well-demarcated erythema, hyperpigmentation and follicular papules. No satisfactory therapy has been widely accepted.
OBJECTIVE: This study was aimed to evaluate the efficiency and complications of a dual-wavelength laser system in the treatment of EFF in Chinese population.
METHODS: Twelve Chinese patients with EFF were enrolled in this study. One side of the face was randomized to receive five successions of treatments at intervals of 6-8 weeks, with the other side spared as control. The parameters were set as follows: energy densities of 6.5-7.5 J/cm(2) with pulsed dye laser (PDL) and 35-50 J/cm(2) with Nd:YAG; pulse duration of 0.5 ms with PDL and 15 ms with Nd:YAG; a delay time of 100 ms between delivery of the two wavelengths. The efficacy was evaluated using subjective assessment and non-invasive measurement.
RESULTS: After five sessions of treatment, over 40% patients achieved more than 50% (moderate or significant) improvement. The efficacy maintained at 3-month follow-up. The values of erythema index and melanin index on treated side were significantly less than those on untreated side after sessions of treatments. Adverse effects of treated side were limited.
CONCLUSION: Using this split-face module, dual-wavelength laser system treatment is proved to be suitable for Chinese EFF. Adverse effects were minimal.
© 2013 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2013        PMID: 24118351     DOI: 10.1111/jdv.12249

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  1 in total

1.  Erythromelanosis Follicularis Faciei: A Case Report and Review of the Literature.

Authors:  Khalid Al Hawsawi; Ohood Aljuhani; Ghassan Niaz; Haneen Fallatah; Abrar Alhawsawi
Journal:  Case Rep Dermatol       Date:  2015-11-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.